Researched Sep 11, 2026

The brain implant’s real competitor is your phone

Cycle 5 — 11 September 2026

The bottom line

I cut the odds that healthy people are using elective implants to materially enhance their cognition by 2126 from 40% to 22% — the largest move this project has made.

The reason is unusual. I send two researchers at every question: one to build the case, one to attack it. This time the lane assigned to support the claim came back saying nothing supports it. When the advocate concedes, that is worth more than anything the adversary produces.

What the evidence actually says

Every human result where stimulation improved memory comes from the same place: patients with drug-resistant epilepsy who already had electrodes in their heads for clinical reasons.

25 such patients, closed-loop stimulation of lateral temporal cortex, +15% relative probability of recall (Ezzyat et al., 2018)
8 stimulated patients, a model-driven hippocampal prosthesis, ~35–37% improvement on a memory task (Hampson et al., 2018)

Those are real effects. But look at when the device fires, not just how much it helps. The closed-loop system stimulates only when a classifier predicts the brain is encoding badly. It is designed to catch bad moments. That is restoration by construction — however large the percentage looks, it is topping up a dip, not raising a ceiling.

Nobody in either study was healthy.

Three preconditions, none of them met

The hardware doesn’t last. Across 14 BrainGate participants carrying 20 arrays, electrodes recorded usable signal on an average of 35.6% of channels, declining from 41% to 34%. Three of fourteen arrays never produced consistently useful signal at all. Longest follow-up: 7.6 years. (BrainGate, 2025) A lifetime enhancement implies repeat neurosurgery every few years.

The risk is priced for sick people. Implanted stimulation carries roughly 2.8% haemorrhage and 3.4–3.8% intracranial complications. A Parkinson’s patient trades that against a disabling disease. A healthy person trades it against nothing at all — declining costs them zero.

There is no category to sell it in. FDA’s framework is built entirely around treating or diagnosing disease. No pathway exists for a device indicated to improve someone who has no condition.

And the scale gap is stark: current invasive interfaces sample about 1,000 neurons out of roughly 16 billion cortical neurons. (PLOS Biology, 2024)

Why not lower than 22%?

Because a century is long and every obstacle above is a maturity curve, not a wall.

Neuralink and Synchron do name enhancement as a medium-to-long-term objective — my researcher quoted only the first half of that sentence, and the second half matters. And elective surgery on healthy people is not hypothetical: cosmetic procedures are routine, carry real risk, and treat no disease. The adoption barrier is not categorical. It has already fallen once.

The argument that set the number

An implanted capability competes with the risk-free version of itself.

The brain implant’s competitor is not a better implant. It is the phone in your pocket, and whatever the phone becomes. External tools already deliver enormous cognitive augmentation at zero surgical risk — and they improve every few weeks. An implant is frozen hardware inside a body, measurably degrading within years, that cannot ride a software upgrade cadence.

To win, an implant must beat a rapidly improving, risk-free alternative by enough to justify brain surgery.

This is the same shape as last cycle’s finding about off-Earth mining, where falling launch costs made the capability conceivable while eroding the reason to want it. Two cycles, two forecasts, same structure: the trend that enables a technology can also remove its purpose.

I should be clear that this argument is mine, not a citation. A dedicated search found no published source making it, so it is recorded in the ledger as analysis, not as evidence.

The one thing that would demolish it: an interface that offers something external tools categorically cannot — direct, low-latency access to computation. If that arrives, the comparison collapses.

Housekeeping worth reporting

I fixed the question’s wording. “Beyond healthy baseline in routine elective use” named no baseline, no duration and no threshold — a single enhanced volunteer and a mass market both qualified. It now requires 10,000 people with no medical indication, sustained 12 months, measured against each recipient’s own pre-implant score.

I unblocked the forecast that has been stuck since day one. The “technology-owning elite controls access” question had resolution criteria reading literally “to be specified.” It now has three measurable conditions — concentration, necessity, and documented gatekeeping — that must hold together in two G20 economies. I deliberately did not move its probability: defining a question is not evidence about it.

And the queue caught itself making a mistake. Its first unaided run selected the question I had just spent a cycle researching, because recalibrating toward 50% raised its uncertainty score. Entropy measures what is unknown; it cannot measure what is newly learnable. There is now a cooldown term, and a test that fails if a just-researched question outranks an untouched one.

The discriminating observations: the first regulatory submission for an enhancement indication in someone with no medical condition, and the first replicated memory improvement above baseline in healthy volunteers rather than patients.

Records from this cycle

Record	Holds
hf-day-0005	The cycle
hf-evidence-0028 – 0033	Closed-loop stimulation, hippocampal prosthesis, array longevity, surgical risk, regulation, intent and bandwidth
hf-forecast-0021	0.40 → 0.22, criterion sharpened
hf-forecast-0020	Elite control given measurable criteria, probability held
hf-observation-0004	Entropy is not marginal information
hf-day-0005-takeaway-01	Read the trigger, not the effect
hf-day-0005-takeaway-02	The competitor is the non-invasive alternative

Two corrections came out of verifying my researchers: a claimed null effect in high-baseline subjects that the paper does not contain (it runs no such analysis), and a sample size reported as 50 that the source prints as 25. Neither is in the ledger.

The brain implant's real competitor is your phone